Company news
Harrow, Inc. (NASDAQ:HROW) news
Harrow, Inc. news releases on 6ix. Latest, Oct 5, 2026: Harrow Closes Acquisition of TYRVAYA®
Press releases & updates
Harrow Closes Acquisition of TYRVAYA®
October 4, 2026
Harrow Closes Acquisition of TYRVAYA®
October 5, 2026
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
September 29, 2026
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
September 30, 2026
Harrow to Participate in Three Investor Conferences in September
September 1, 2026
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
August 20, 2026
Harrow Announces Second Quarter 2026 Financial Results
August 10, 2026
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
August 6, 2026
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
July 27, 2026
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
July 20, 2026
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
July 1, 2026
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare
June 10, 2026
Harrow to Present at William Blair’s 46th Annual Growth Stock Conference
May 26, 2026
Harrow Announces First Quarter 2026 Financial Results
May 11, 2026
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
April 27, 2026
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%
April 15, 2026
LogiCare3PL Selected as Distribution Partner by Harrow
April 14, 2026
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
March 23, 2026
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
March 23, 2026
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
March 17, 2026
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference
March 3, 2026
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
March 2, 2026
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
March 2, 2026
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
February 18, 2026
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits
February 17, 2026
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
February 3, 2026
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
February 1, 2026
Harrow to Present at Two Investor Conferences in December
November 23, 2025
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
November 17, 2025
Harrow Announces Third Quarter 2025 Financial Results
November 9, 2025
Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025
October 26, 2025
ImprimisRx Announces Leadership Changes
October 5, 2025
Harrow to Acquire Melt Pharmaceuticals
September 25, 2025
Harrow Launches Harrow Access for All (HAFA)
September 24, 2025
Harrow Announces Agenda and Speakers for Investor & Analyst Day
September 14, 2025
Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030
September 7, 2025
Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030
September 7, 2025
Harrow Announces Second-Quarter 2025 Financial Results
August 10, 2025
Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference
August 5, 2025
Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025
July 28, 2025
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
July 16, 2025
Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications
June 17, 2025
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
June 8, 2025
Harrow to Present at Two Investor Conferences in May
May 13, 2025
Harrow Announces First-Quarter 2025 Financial Results
May 7, 2025
Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025
May 4, 2025
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)
April 23, 2025
Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients
April 9, 2025
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025
March 26, 2025
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
March 26, 2025